TP53 and carcinoma: This seems to stand in contrast to human CACs, in which APC mutations are thought to inhibit beta-catenin degradation and thereby promote nuclear translocation, although detailed data in humans is missing [18], whereas the high expression of phosphorylated p53 observed in these tumors is congruent with results in human UC-associated carcinomas [13].